EUCTR2015-004702-42-ES进行中（未招募）1 期
A Multi-Center, Parallel Group, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of a Single Subcutaneous Injection of RG-101 Combined with Oral GSK2878175 Taken Once Daily for 6, 9, or 12 Weeks in Treatment Naïve, Genotype 1 and 3, Chronic Hepatitis C Patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Adults aged 18 to 75 (inclusive) infected with HCV genotype 1 or 3;
- •2. Body mass index (BMI): 18.0 - 35.0 kg/m2;
- •[BMI (kg/m2) = Body weight (kg) ÷ Height2 (m2)];
- •3. Clinical and laboratory findings consistent with a clinical diagnosis of CHC, including:
- •- Previous documentation of positive HCV serology (HCV antibody or HCV RNA) at least 24 weeks prior to enrolment,
- •- Positive HCV serology (HCV antibody or HCV RNA) less than 24 weeks with a prior remote risk factor (more than 24 weeks prior to Screening) for the acquisition of hepatitis C,
- •- Serum HCV RNA > or= 375,000 copies/mL or > or= 75,000 IU/mL at Screening;
- •4. Subjects must have been treatment-naïve and had not received prior treatment with any interferon, immunomodulatory agent, or direct acting antiviral agent (DAA) or ribavirin containing regimen for HCV;
- •5. Screening hematology, clinical chemistries, coagulation and urinalysis are not clinically significant and the following criteria are met:
- •- Platelets > 100x109/L
- •- Total white blood cells > 3.0x109/L and absolute neutrophil count > 1.5x109/L
- •- Hemoglobin > 10.95 g/dL for females and > 11.92 g/dL for males
- •- Total and direct bilirubin < 1.5x upper level of normal (ULN)
- •- Alanine aminotransferase (ALAT) < 5x ULN
- •- Aspartate aminotransferase (ASAT) < 5x ULN
- •- ALP < 2x ULN
- •- Albumin > or = 3.5 g/dL
- •- Serum creatinine within normal limits or increased up to 1.5x ULN and estimated creatinine clearance rate as calculated by the Cockcroft-Gault formula > 60 mL/min.
- •Cockroft-Gault formula: ((140 - age) x weight (in kilograms) x constant) / serum creatinine (in µmol/L), where constant is 1.23 for men and 1.04 for women
- •Note: At the discretion of the Investigator, screening laboratory testing may be repeated once to confirm out of-range (exclusionary) results.
- •6. Female subjects must be of non-childbearing potential and must have undergone one of the following sterilization procedures at least 6 months prior to dosing:
- •a. hysteroscopic sterilization;
- •b. bilateral tubal ligation or bilateral salpingectomy;
- •c. hysterectomy;
- •d. bilateral oophorectomy;
- •or be postmenopausal with amenorrhea for at least 1 year prior to dosing and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status as per Investigator judgment;
- •7. Male subjects with female partners of childbearing potential must use one of the following contraception methods from the time of the first dose of study medication to the last follow-up visit in the Short Term Follow-up Period (12 weeks after the last dose of study medication):
- •a. Male condom plus partner use of one of the following highly effective contraceptives:
- •- Contraceptive subdermal implant;
- •- Intrauterine device (IUD) or intrauterine system (IUS);
- •- Combined estrogen and progestogen oral contraceptive;
- •- Injectable progestogen;
- •- Contraceptive vaginal ring;
- •- Percutaneous contraceptive patches;
- •b. Documented sterilization of the male subject. For this definition, documented refers to the outcome of the Investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records;
- •c. Abstinence, defined as sexual inactivity consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception;
- •8. Negative results on the screening al
排除标准
- •1. Other known cause of liver disease except for CHC;
- •2. History or symptoms of decompensated liver disease: Child-Pugh Class B or C, including ascites, hepatic encephalopathy, esophageal variceal bleeding, cirrhosis, or other signs of hepatic insufficiency or portal hypertension;
- •3. History of hepatocellular carcinoma or current liver mass consistent with malignancy on imaging studies;
- •4. Serum alpha-fetoprotein (AFP) > 50 ng/mL at Screening;
- •5. Concurrent clinically significant medical diagnosis (other than hepatitis C-related conditions) that would potentially interfere with the subjects study compliance or confound study results including but not limited to: significant or unstable cardiac disease (e.g., prolonged QT syndrome [torsades de pointe], unstable angina, myocardial infarction, diastolic dysfunction, congestive heart failure, significant arrhythmia, coronary heart disease, and/or clinically significant ECG abnormalities); cancer; uncontrolled seizure disorder; ascites; chronic infection other than HCV (e.g., tuberculosis); uncontrolled diabetes, and/or uncontrolled thyroid disease;
- •6. Evidence of cirrhosis, as determined by any one of the following:
- •a. FibroSure/FibroTest score >0.58 or Fibroscan score indicative of cirrhosis (> or =14.5 kPa); or
- •b. Liver biopsy with a fibrosis stage indicative of cirrhosis as classified by a local pathologist (defined as Knodell > 3, Metavir > 2, Ishak > 4, or Batts and Ludwig > 2). Both incomplete and transition to cirrhosis (e.g., Metavir score 3) are considered as cirrhosis; or
- •c. History of ascites, hepatic encephalopathy, or esophagogastric varices;
- •7. Concurrent social conditions (e.g., drugs, alcohol) which would potentially interfere with the subject's study compliance;
- •8. Use of anticonvulsants, antimycobacterials, analeptics and herbal supplements that may interact with the bioavailability of the investigational product or oral DAA agents; or other alternative medicines that may have influence on the disease outcome;
- •9. Mental handicap or history of or current significant psychiatric disease (which might impair ability to provide informed consent);
- •10. Clinically significant illness within 30 days prior to Screening;
- •11. Have used an investigational drug or has participated in an investigational study with a licensed drug within 30 days or 5 half lives, whichever is longer, prior to study drug administration;
- •12. History of relevant drug and/or food allergies;
- •13. Donation of more than 500 mL of blood within 60 days prior to drug administration. Donation of more than 1.5 liters of blood (for men) / more than 1.0 liter of blood (for women) in the 6 months prior to Screening;
- •14. The following family history of cardiac disease:
- •- prolonged QT syndrome (Torsade de Pointes) or sudden cardiac death;
- •- first-degree relative with myocardial infarction at premature age (< or = 45 years for male relative; < or = 55 years for female relative);
- •15. Evidence of clinically significant pulmonary disease, as determined by any of the following:
- •a. Known (past or current) history of significant asthma, emphysema, chronic obstructive pulmonary disease, and/or interstitial lung disease; or
- •b. Abnormal pretreatment spirometry results.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial in patients with the liver disease caused by the hepatitis C virus for assessment of safety and efficacy of one injection of test product RG-101 given in combination with test product GSK2878175 that is to be taken by mouth once daily for 6, 9, or 12 weeksTreatment Naïve, Genotype 1 and 3, Chronic Hepatitis C PatientsMedDRA version: 18.1Level: LLTClassification code 10076831Term: Chronic hepatitis C genotype 3System Organ Class: 100000004862MedDRA version: 18.1Level: LLTClassification code 10074391Term: Chronic hepatitis C virus genotype 1System Organ Class: 100000004862EUCTR2015-004702-42-GRRegulus Therapeutics Inc.24
进行中（未招募）
1 期
A clinical trial in patients with the liver disease caused by the hepatitis C virus for assessment of safety and efficacy of one injection of test product RG-101 given in combination with test product GSK2878175 that is to be taken by mouth once daily for 6, 9, or 12 weeksTreatment Naïve, Genotype 1 and 3, Chronic Hepatitis C PatientsMedDRA version: 19.0Level: LLTClassification code 10076831Term: Chronic hepatitis C genotype 3System Organ Class: 100000004862MedDRA version: 19.0Level: LLTClassification code 10074391Term: Chronic hepatitis C virus genotype 1System Organ Class: 100000004862EUCTR2015-004702-42-HURegulus Therapeutics Inc.24
已完成
3 期
An Open Label, Parallel Group, Multi-centre, Phase III Study to Assess the Efficacy and Safety of D961H for the Maintenance Therapy Following Initial Treatment in Japanese Paediatric Patients With Reflux Esophagitis and for the Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer in Japanese Paediatric Patients Treated With Non-steroidal Anti-inflammatory Drugs or Low-dose AspiriReflux Esophagitis, Gastric Ulcer, Duodenal UlcerJPRN-jRCT2080223965AstraZeneca KK60
进行中（未招募）
1 期
phase I / III study to assess the safety, pharmacokinetics, pharmacodynamics and efficacy in Japanese paediatric patientsJapanese paediatric patients 1 to 14 years old with gastrointestinal acid related diseasesEUCTR2016-003775-22-Outside-EU/EEAAstraZeneca K.K.50
未知
3 期
An Open-label, Parallel-group, Multi-centre, Phase 1/3 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10mg and D961H 20mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related DiseasesGastric Ulcer(GU), Duodenal Ulcer(DU), Anastomotic Ulcer(AU), Non-erosive Reflux Esophagitis Disease(NERD), Reflux Esophagitis(RE), Zollinger-Ellison SyndromeJPRN-jRCT2080222552AstraZeneca